These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 21410975)

  • 1. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes.
    Ratner R; Han J; Nicewarner D; Yushmanova I; Hoogwerf BJ; Shen L
    Cardiovasc Diabetol; 2011 Mar; 10():22. PubMed ID: 21410975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.
    Ridge T; Moretto T; MacConell L; Pencek R; Han J; Schulteis C; Porter L
    Diabetes Obes Metab; 2012 Dec; 14(12):1097-103. PubMed ID: 22734440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
    Wysham CH; Rosenstock J; Vetter ML; Dong F; Öhman P; Iqbal N
    Diabetes Obes Metab; 2018 Jan; 20(1):165-172. PubMed ID: 28685973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
    Diamant M; Nauck MA; Shaginian R; Malone JK; Cleall S; Reaney M; de Vries D; Hoogwerf BJ; MacConell L; Wolffenbuttel BH;
    Diabetes Care; 2014 Oct; 37(10):2763-73. PubMed ID: 25011946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.
    Madsbad S; Kielgast U; Asmar M; Deacon CF; Torekov SS; Holst JJ
    Diabetes Obes Metab; 2011 May; 13(5):394-407. PubMed ID: 21208359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.
    Malloy J; Meloni A; Han J
    Postgrad Med; 2013 May; 125(3):58-67. PubMed ID: 23748507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
    Mentz RJ; Bethel MA; Gustavson S; Thompson VP; Pagidipati NJ; Buse JB; Chan JC; Iqbal N; Maggioni AP; Marso SP; Ohman P; Poulter N; Ramachandran A; Zinman B; Hernandez AF; Holman RR
    Am Heart J; 2017 May; 187():1-9. PubMed ID: 28454792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.
    Simó R; Guerci B; Schernthaner G; Gallwitz B; Rosas-Guzmàn J; Dotta F; Festa A; Zhou M; Kiljański J
    Cardiovasc Diabetol; 2015 Sep; 14():116. PubMed ID: 26338040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects.
    Mundil D; Cameron-Vendrig A; Husain M
    Diab Vasc Dis Res; 2012 Apr; 9(2):95-108. PubMed ID: 22496442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide.
    Pencek R; Brunell SC; Li Y; Hoogwerf BJ; Malone J
    Endocr Pract; 2012; 18(2):227-37. PubMed ID: 22446132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes.
    Henry RR; Logan D; Alessi T; Baron MA
    Clin Ther; 2013 May; 35(5):634-645.e1. PubMed ID: 23578605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.
    Esposito K; Mosca C; Brancario C; Chiodini P; Ceriello A; Giugliano D
    Curr Med Res Opin; 2011 Aug; 27(8):1519-28. PubMed ID: 21663496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis.
    Sun F; Yu K; Yang Z; Wu S; Zhang Y; Shi L; Ji L; Zhan S
    Exp Diabetes Res; 2012; 2012():230624. PubMed ID: 23365557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
    Lecube A; Bueno M; Suárez X
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():23-7. PubMed ID: 25437462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
    Blevins T; Pullman J; Malloy J; Yan P; Taylor K; Schulteis C; Trautmann M; Porter L
    J Clin Endocrinol Metab; 2011 May; 96(5):1301-10. PubMed ID: 21307137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
    Diabetes Obes Metab; 2014 Jan; 16(1):38-47. PubMed ID: 23829656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials.
    Monami M; Cremasco F; Lamanna C; Colombi C; Desideri CM; Iacomelli I; Marchionni N; Mannucci E
    Exp Diabetes Res; 2011; 2011():215764. PubMed ID: 21584276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.